15 CUSHING, IRVINE, CA
Financial Results, Press Release
Insight Molecular Diagnostics Enters Specimen Collection Agreement with Quest...
Announces $26.0 Million Registered Direct Offering
Investor Presentation
Changes in Board, Management or Compensation
Reports Q2 2025 Results and Momentum Toward GraftAssureDx Launch
Q3
Q2
Q1
FY 2024
FY 2023
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(3)
Effectiveness Notice
S-1
Notice of Exempt Offering of Securities
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership
Amended Schedule 13D - Ownership Report
Amended Statement of Changes in Beneficial Ownership
Correspondence
Submission Upload